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Treatment of Streptococcal Endocarditis
With a Single Daily Dose of
Ceftriaxone Sodium for 4 Weeks
Efficacy and Outpatient Treatment Feasibility
Patrick Francioli, MD; J\l=e'\r\l=o^\meEtienne, MD; Rolf Hoign\l=e'\,MD;
Jean-Pierre Thys, MD; Andreas Gerber, MD
Objective.\p=m-\Toevaluate the efficacy and safety of ceftriaxone sodium in the
treatment of streptococcal endocarditis.
Design.\p=m-\Anopen, multicenter, noncomparative study with a follow-up of
patients for 4 months to 5 years.
Setting.\p=m-\Internalmedicine wards and outpatient clinics of hospitals of various
sizes in three European countries.
Patients.\p=m-\Fifty-ninepatients with defined criteria for streptococcal endo-
carditis.
Intervention.\p=m-\Ceftriaxonesodium administered at a once-daily dose of 2 g for
4 weeks.
Main Outcome Measures.\p=m-\Clinicaloutcome and microbiological cure rate.
Results.\p=m-\Amongthe 59 patients, 55 completed the treatment and were
followed up for 4 months to 5 years. No patients showed evidence of relapse.
Treatment was completely uneventful in 42 patients (71%). A cardiac valve was
replaced in four patients (7%) receiving antimicrobial therapy and in six patients(10%) who had completed antimicrobial therapy. One of the 10 valves taken for
culture at surgery was positive, but only for microorganisms that were different from
the microorganism isolated before the treatment. The treatment had to be inter-
rupted in four patients because of drug allergy. Other side effects were mild
except for two cases of reversible neutropenia. The treatment was easy to
administer: 27 patients (46%) had no permanent intravenous catheter at any
time, seven patients (12%) had such a catheter for less than 4 days. Twenty\x=req-\
three patients (39%) were discharged from the hospital less than 2 weeks after
admission.
Conclusions.\p=m-\Ceftriaxonesodium administered at a once-daily dose of 2 g
appears to be an effective and safe treatment of streptococcal endocarditis. In
hospitals, this agent may be more convenient to administer than penicillin G
with or without aminoglycosides. Some patients may even be treated as outpa-
tients.
(JAMA. 1992;267:264-267)
ANTIMICROBIAL treatment of infec¬
tive endocarditis (IE) has recently been
reviewed by the Committee ofthe Amer¬
ican Heart Association's Council on Car¬
diovascular Disease in the Young.1
Streptococcal IE can be treated success¬
fully either with high-dose parenteral
For editorial comment see
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administration of aqueous crystalline
penicillin G for 4 weeks, or alternatively
with a 2-week course of high dosages of
penicillin combined with an aminogly-
coside administered parenterally. With
both types of treatment, the cure rate is
better than 98%.2 If a patient is allergic
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Table 1 —Minimal Inhibitory Concentration in Micrograms per Milliliter for Ceftrlaxone Sodium and Penicillin
of 60 Strains of Streptococci in 59 Patients
No. of
Strains
Ceftriaxone Sodium,
µ ,/   -
MIC„ Range
Penicillin, µ /mL
Mie» Range
Streptococcus sanguis .125  64-.25
Streptococcus bovis .125 125-.25
Streptococcus mutans .032 .032 .064 .064
Streptococcus mitis .125 .032-. 125 .032
Other streptococci .032 064 .032-064
to penicillin, a first-generation cephalo-
sporin or vancomycin hydrochloride can
be given.
Ceftriaxone sodium, a third-genera¬
tion cephalosporin, has excellent in vitro
activity against Streptococcus viridans
and nonenterococcal streptococci.3 Be¬
cause of its half-life of 6 to 9 hours, cef¬
triaxone administered once daily pro¬
vides effective serum levels for 24 hours,
both after intravenous (IV) and intra¬
muscular (IM) injections.4,5 This has per¬
mitted the treatment of severe infec¬
tions with only one IV or IM injection
daily.6"8 This simplified regimen obvi¬
ates the need for an IV access (except
for the daily infusion), requires only one
preparation ofantibiotics daily, and con¬
sequently offers the possibility of home
therapy for some patients.6"8
The purpose ofthe present study was
to test the efficacy and safety of ceftri¬
axone sodium at a once-daily dose of 2 g(IV or IM) in monotherapy of IE due to
ceftriaxone-susceptible streptococci. It
was designed as an open, multicenter
trial. The trial was noncomparative,
since streptococcal IE has become a rare
disease, and the results with penicillin
treatment are well known.
PATIENTS AND METHODS
The criteria for diagnosis of IE were
derived from those developed by Von
Reyn et al.9 Patients had to meet two
conditions. First, at least two blood cul¬
tures (two bottles for each blood cul¬
ture) obtained on two separate occasions
had to be positive for nonenterococcal
streptococcus. When only two or three
blood cultures were obtained, all bottles
had to be positive. When more than three
blood cultures were obtained, at least
70% of them had to be positive. Second,
patients must have had a new régur¬
gitant heart murmur (or a definite
change in a preexisting one) or a pre¬
disposing heart disease and vascular
phenomena.
Patients were excluded from the study
if they had received other antibiotics for
more than 3 days, had allergic reactions
to cephalosporins, or had severe renal
impairment (creatinine clearance
<0.167mL/s).
Ceftriaxone sodium was administered
at a daily dose of2 g by short IV infusion(2 g diluted in 50 mL of 5% glucose) or
by IM injections (2 g mixed with 1%
lidocaine and injected in the gluteal mus¬
cles) for 4 weeks. The requirements for
treatment by a permanent indwelling
IV catheter were not strictly defined.
When the condition of the patient per¬
mitted and there was an appropriate
outpatient setting, patients were dis¬
charged from the hospital. They were
asked to refrain from activities requir¬
ing permanent attention, such as driv¬
ing a car.
Patients were assessed daily during
hospitalization and at least once a week
after discharge until the end of the treat¬
ment. Follow-up visits were carried out
once between weeks 2 and 4, and again
between 3 and 6 months after comple¬
tion of treatment. Most patients were
followed up for longer periods.
Serial laboratory investigations in¬
cluding hématologie and chemical anal¬
ysis of the blood, urine analysis, blood
cultures, and drug sensitivity tests were
performed before, during, and after
treatment.
The strains of streptococci isolated
from blood cultures were identified by
API 20 Strep system (Api System SA,
France). The minimum inhibitory con¬
centrations (MICs) were determined by
the macro-tube dilution technique in
Müller-Hinton broth.3
The study was approved by the eth¬
ical committee of the organizing insti¬
tution (Lausanne, Switzerland).
RESULTS
Sixty-two patients with active, non-
enterococcal streptococcal IE were in¬
cluded. Of these, three had to be ex¬
cluded because they had received other
antibiotics for more than 3 days before
ceftriaxone therapy was started. Thus,
59 patients were evaluated. Five cen¬
ters (Lausanne, Switzerland, Lyons,
France, Bern, Switzerland, Brussels,
Belgium, and Burgdorf, Switzerland)
provided most of the cases, and eligible
patients were included consecutively.
The rest of the patients were provided
by several hospitals under the direct
supervision of the center at Lausanne.
Of the 59 patients, 41 were men and
18 were women. The median age was 59(range, 19 to 87 years). The duration of
symptoms before treatment ranged from
5 to 120 days, and six patients reported
having symptoms for at least 3 months.
Forty-six patients had a known under¬
lying valvular or congenital cardiac ab¬
normality. Infection affected the mitral
valve alone in 28 patients (47%), the
aortic valve alone in 20 patients (34%),
mitral and aortic valves in five patients(8%), pulmonary valves in two patients(3%), and a ventricular septal defect in
two patients (3%).
Sixty different strains of streptococci
could be isolated from the 59 patients(Table 1). None was identified as a nu¬
tritionally deficient variant. All strains
had MICs for ceftriaxone below
0.125 µg/mL, except for one strain of
Streptococcus sanguis with a MIC of
0.25 µg/mL. The MICs for ceftriaxone
were one dilution above the MICs of
penicillin for all strains of streptococci
except those of Streptococcus bovis,
which were one or two dilutions below
those for penicillin.
Twelve patients were treated with an¬
tibiotics other than ceftriaxone for 1, 2, or
3 days (four patients for each day) before
the definite diagnosis of IE was estab¬
lished by blood culture results. These pa¬
tients were then switched to ceftriaxone.
In four patients, the physician in
charge decided to extend the treatment
beyond 4 weeks: one patient presented
with an associated spondylodiskitis (42
days), one had a spondylodiskitis and a
cerebral mycotic aneurysm (60 days),
one had a pacemaker (42 days), and one
violated the protocol (42 days). In four
patients, the treatment was interrupted
because ofadverse reactions to the drug:
two patients developed an allergic rash
and two had a second occurrence of fe¬
ver, which was considered a drug reac¬
tion. For these patients, the treatment
was continued with penicillin. The re¬
maining 55 patients (93%) were followed
up for 4 months to 5 years after the end
oftreatment. No patients presented with
clinical signs or laboratory evidence of
relapse. Three patients had a second
episode of IE due to different microor¬
ganisms: one patient had a second epi¬
sode of IE 4 years later due to a differ¬
ent strain oîSviridans, another patient
had a recurrence of endocarditis due to
Haemophilus influenzae 1 year after
the streptococcal episode, and a third
patient is described below.
No patient died during treatment. One
patient died suddenly 3 months after
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completion oftreatment. Blood cultures
had been negative 1 month prior to
death. No autopsy was performed.
Ten patients (17%) required cardiac
surgery some time after the initiation of
treatment. In eight of these patients,
valve replacement was performed be¬
cause ofhemodynamic deterioration: two
patients required the procedure during
the course of the treatment (day 4 and
day 23) and six required the procedure
after its completion. All had signs of
congestive heart failure before initia¬
tion of therapy. Two patients had valve
replacements because of recurrent em¬
boli (on day 7 and day 12). The valves
removed at operation were negative for
streptococcal infection in nine of 10 pa¬
tients, as evidenced by direct micro¬
scopic examination and cultures. The
10th patient was an unusual case: he
was treated with ceftriaxone sodium at
1 g per day for 6 weeks because of a
protocol violation. The initial organism
was Streptococcus morbillorum with an
MIC of0.125 µg/mL. He underwent den¬
tal extraction 4 weeks after initiation of
therapy. On that occasion, he also re¬
ceived one dose of gentamicin sulfate.
Three days after completion of treat¬
ment, he was profoundly neutropenic.
He became febrile soon after and de¬
veloped symptoms suggestive of multi¬
ple cerebral emboli, prompting an im¬
mediate valve replacement. Examina¬
tion of the valve disclosed acute en¬
docarditis. Cultures were positive for
Streptococcus mitis and Corynebacte-
rium xerosis. He was treated with pen¬
icillin and gentamicin for 6 additional
weeks and eventually recovered.
Five patients developed emboli while
receiving ceftriaxone. Blood cultures
taken at the time of the episodes were
sterile. Emboli affected multiple, small
peripheral vessels in three patients (on
days 3, 7, and 12) and a single major
peripheral artery in two patients (on
days 3 and 12). Two of the three pa¬
tients with multiple emboli underwent
cardiac valve replacement. Cultures
taken of the excised valves were nega¬
tive for streptococcal infection. Echocar-
diograms were performed on 51 (86%)
of the 59 patients. Cardiac vegetations
were seen in 22 (37%) of them and were
detectable in only three of the five pa¬
tients presenting with emboli.
Drug-related side effects were as fol¬
lows: two patients experienced neutro-
penia, one on day 26 and the other 3 days
after completion of a 42-day course of
therapy (protocol violation). Complete
blood counts returned to normal 5 to 7
days after cessation ofceftriaxone ther¬
apy. Pain and phlebitis at the site of IV
injection occurred in six patients (10%),
transient gastrointestinal discomfort in
four patients (7%), superficial and tran¬
sient Candida infection in three pa¬
tients (5%), fever ofpresumably allergic
origin in three patients (5%) (two
prompting treatment interruption,
both on day 15), rash in two patients(3%) (both prompting treatment inter¬
ruption on days 2 and 10), dysgeusia in
one patient (2%), and laboratory abnor¬
malities in five patients (8%) (two with
moderate hypereosinophilia, one with
positive results of direct antiglobulin
test and two with increases in ami-
notransferase levels). All side effects re¬
solved either during therapy or after the
end of treatment.
Many patients could be treated with¬
out a permanent indwelling IV cathe¬
ter. In these patients, the drug was ad¬
ministered daily through the placement
of a butterfly needle either as a short
infusion or as a slow IV injection (Table
2). Twenty-seven patients (46%) had no
permanent indwelling catheter at any
time, seven (12%) had such a catheter
for less than 4 days. In the other 21
patients, the IV line was maintained for
more than 4 days either because of the
concomitant administration of other
medications or because the initial cath¬
eter was well tolerated and the physi¬
cians decided to maintain it for the ad¬
ministration ofceftriaxone. In seven pa¬
tients, treatment was administered par¬
tially or totally by IM injections (for
periods of 16, 16, 20, 24, 28, 28, and 52
days, the last patient being the one with
spondylodiskitis and cerebral mycotic
aneurysm). The IM injections were well
tolerated. Twenty-three patients could
be discharged from the hospital after
less than 2 weeks: seven patients either
were not hospitalized at all or were
hospitalized for less than 2 days, two
patients stayed for less than 7 days
and 14 patients for 8 to 14 days. In
these patients, the drug was adminis¬
tered either in the outpatient clinics
of the participating hospitals or in the
physicians' offices. In addition, seven
patients were hospitalized for the en¬
tire course of treatment only because
of the absence of outpatient treat¬
ment facilities.
COMMENT
Antibiotic regimens recommended by
the American Heart Association for the
treatment of streptococcal, nonentero¬
coccal endocarditis require the admin¬
istration of several IV or IM injections
of the drugs daily,1 thus, hospitalization
is almost always unavoidable. In the
present study, 59 patients were treated
with ceftriaxone sodium administered
once daily at a dose of 2 g by IV or IM
injections. Drug allergy prompted the
interruption of treatment in four pa-
Table 2. —Intravenous Requirements and Duration
of Hospitalization of 55 Patients With Streptococcal
Endocarditis Treated With One Daily Injection of
2 g of Ceftriaxone Sodium for 4 Weeks (51 Patients)
or 6 Weeks (4 Patients)
Mode of Treatment, d No. of Patients
Intravenous catheter
None* 27
<4 7
24 21
Intramuscular Injection
7-52 7
Hospital stay
<2 7
<7 2
<15 14
a15 32f
*Drug was administered by short, once dally Infusion,
tlncludes 7 patients for which hospitalization beyond
2 weeks was due to nonmedlcal reasons.
tients. All 55 assessable patients re¬
sponded clinically and microbiologically,
and no relapse occurred after cessation
of treatment. No patient died during
treatment. Although this study was not
comparative, the results are similar to
those studies that reported using pen¬
icillin alone for 4 weeks or regimens of
penicillin given with streptomycin sul¬
fate for 2 weeks. These regimens an¬
ticipate a cure rate of at least 98%.10"12
The present study also confirms and
extends the results of a recently pub¬
lished study in which 30 patients
were treated successfully with either
2 g of ceftriaxone sodium per day for
4 weeks or the same dosage for 2
weeks, and then given amoxicillin
orally for 2 weeks.13
Eight (13%) of our patients required
a valve replacement because of hemo-
dynamic deterioration. All had some de¬
gree of cardiac failure on initiation of
therapy. Cultures taken of the excised
valves during or after treatment were
sterile in all but one patient who had a
second episode of endocarditis. The re¬
placement rate is similar to that reported
by some authors11 but somewhat lower
than the 29% reported by others.14 Al¬
though the eligible patients coming to
our study through the five main centers
were included consecutively, some pa¬
tients from the hospitals connected with
the center at Lausanne may have been
referred because the physicians knew
about the possibility ofoutpatient treat¬
ment. Thus, there may have been some
bias toward less severe cases included
in the present study. This is also sug¬
gested by our low mortality rate and by
the fact that only six patients (10%) re¬
ported having symptoms for more than
3 months, as compared with 18% to 20%
of patients in other studies.12,14
The most severe side effect was neu-
tropenia, which was observed in two
patients (one of whom was treated for
42 days). This is a known side effect of
penicillins and cephalosporins, which is
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reversible within 5 to 7 days after dis¬
continuation of therapy. It is observed
in 2% to 4% of patients treated with
these drugs, mostly after high dosage
and prolonged use.615 Thus, benzylpen-
icillin administered at a mean daily dose
of 16.9 g had to be interrupted after 19
to 23 days in seven of 14 patients with
endocarditis because of fever and neu-
tropenia.15 This underlines the neces¬
sity for regular hematological monitor¬
ing patients treated for more than 2
weeks with high dosages of ß-lactam
antibiotics. Other recorded side effects
were mild and did not require with¬
drawal of treatment, except for allergic
manifestations in four patients.
One of the main advantages of ceftri¬
axone relates to its pharmacokinetic
properties, which have allowed treat¬
ment of severe infections with one daily
administration by intermittent IV in¬jection, heparin lock, or IM injection.6"8
This obviates the risks and inconve¬
niences inherent in any intravascular
device and permits substantial cost sav¬
ings in professional time necessary for
drug administration and material costs,
both for inpatients and outpatients.6·7,13
In the case of IE, patients eligible for
outpatient treatment obviously need to
be carefully selected. The most frequent
complications of IE include congestive
heart failure and emboli. Although he-
modynamic deterioration may occur in
any patient, this is more likely to affect
patients who have some degree of heart
failure on admission. Among the 91 pa¬
tients with streptococcal IE reported
by Wilson et al,14 only one patient had
progression ofheart failure during ther¬
apy, and among the 16 who underwent
aortic valve replacement, none had sud¬
den-onset aortic insufficiency. In the
present study, hemodynamic deteriora¬
tion prompted valve replacement in only
two patients who were undergoing ther¬
apy. Both had signs of cardiac failure at
the time antibiotic therapy was started,
and were kept in the hospital during the
treatment. Therefore, careful evalua¬
tion of the cardiac function should allow
the selection of patients who are at low
risk for the development of cardiac in¬
sufficiency during outpatient treatment.
Other cardiac complications, such as my-
ocardial infarction or sudden death
caused by occlusion of the coronary ar¬
teries by cardiac vegetations, are only
rare complications of streptococcal
IE.11,16,17
Arterial emboli are the second most
common complications of IE. However,
emboli mostly occur before or within
the first few days after initiation of ap¬
propriate antibiotic therapy1820 and are
less frequent in streptococcal IE than in
IE due to more virulent microorgan¬
isms.19·20 Moreover, the occurrence of
major emboli is associated with the pres¬
ence of large cardiac vegetations seen in
echocardiograms,21·22 so that it appears
possible to select patients who are at
low risk for such complication for out¬
patient treatment. Appropriate coun¬
seling for avoiding activities that may
endanger the patient or other people in
case of a sudden event during therapy
is, nevertheless, indicated.
Infectious central nervous system
complications, such as mycotic aneu-
rysms or brain abscesses, may occur in
IE. Due to its relatively good cerebrospi-
nal fluid penetration, ceftriaxone should
provide protection against such possi¬
bilities and may be a better choice than
the first-generation cephalosporins cur¬
rently recommended as alternative reg¬
imens to penicillin.1
It may be argued that the relatively
narrow antimicrobial spectrum of pen¬
icillin is more appropriate for the treat¬
ment of IE due to sensitive microor¬
ganisms. However, it is unlikely that
the use of a broad-spectrum antibiotic
for the treatment of IE would contrib¬
ute to the emergence of resistance to
cephalosporins since streptococcal IE is
a rare disease and the number of pa¬
tients treated remains limited. The num¬
ber of such patients may even be re¬
duced with good compliance to antibi¬
otic prophylaxis as emphasized in the
recently revised recommendations ofthe
American Heart Association.23
In conclusion, a 4-week course of a
once-daily dose of ceftriaxone is effica¬
cious and safe for the treatment ofstrep¬
tococcal endocarditis. It is easy to ad¬
minister, requires only one daily injec¬
tion, and permits outpatient treatment
for selected patients. However, before
considering outpatient treatment, the
patients should be carefully evaluated
and stabilized in the hospital.
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